

October 15, 2025

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
--	--

Dear Sir/Madam,

Sub.: Outcome of Board Meeting held on Wednesday, October 15, 2025

Ref.: Compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With regards to the captioned matter and in compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (“**Listing Regulations**”), as amended, this is to inform you that at the meeting of the Board of Directors of the Company which commenced at 05:30 P.M. and concluded at 06:30 P.M. today i.e. Wednesday, October 15, 2025, the Board of Directors of the Company have inter alia approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025 along with Statement of Assets and Liabilities and Cash Flow Statement for the half year ended September 30, 2025 are enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to “**Limited Review**” and the same are enclosed herewith.

2. Grant of Options under Rossari Employee Stock Option Plan - 2019

Pursuant to Regulation 30 of the Listing Regulations and ratification of the Rossari Employee Stock Option Plan - 2019 (“**ESOP 2019**”) by the Members of the Company on April 17, 2021, and as per the recommendation of Nomination and Remuneration Committee of the Company, the Board has approved to grant of 35,000 Stock Options under ESOP 2019.

Details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular no. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as **Annexure-I**.



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

✉ info@rossari.com

🌐 www.rossari.com

3. Allotment of Equity Shares under the Rossari Employee Option Plan - 2019

With reference to the in-principle approval received from BSE Limited Letter Ref. No. DCS/FL/MJ/ESOP-IP/1257/2021-22 dated May 25, 2021 and National Stock Exchange of India Limited Letter Ref. No. NSE/LIST/26888 dated May 28, 2021 for issue and allotment of 1500000 Equity Shares of Rs. 2/- each to be issued under Rossari Employee Stock Option Plan - 2019 (“**ESOP 2019**”), the Board of Directors of the Company approved the allotment of 14,400 Equity Shares of Rs. 2/- each fully paid to the grantees on exercise of the options granted to them pursuant to ESOP 2019.

The said Equity shares shall rank pari passu, in all respects with the existing equity shares of the Company. Consequent, to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company stands increased to Rs. 11,07,62,732 consisting of 55381366 Equity Shares of Rs. 2/- each.

Details required under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure - II**.

4. Investment in Rossari International Limited Company, wholly owned subsidiary of the Company

Furtherance to our intimation dated November 30, 2024, December 24, 2024 and pursuant to Regulation 30 of the Listing Regulations, we hereby inform that the Board of Directors of the Company have accorded approval for an additional investment upto USD ~8 million, in one or more tranches in Rossari International Limited Company.

Details as required pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular no. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024 are enclosed as **Annexure - III**.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited



Parul Gupta

Head - Company Secretary & Legal

Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

Annexure-I
Detailed intimation as per Regulation 30 of the Listing Regulations

Sr. No.	Particulars	Details
1.	Brief details of options granted	Grant of 35000 Options to eligible employees.
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes, the Rossari Employee Stock Option Plan – 2019 (ESOP 2019) has been formulated and adopted by the Company in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
3.	Total number of shares covered by these options	35000 Equity Shares of the face value Rs. 2/- each (As per terms, each Option will be converted into one Equity Share of the Company).
4.	Pricing Formula/ Exercise Price	As per the ESOP 2019, the exercise price of the Options will be decided by the Board / Nomination & Remuneration Committee (“NRC”). The exercise price determined is Rs. 661 per Option.
5.	Options Vested/ Vesting Schedule	The Options shall vest as under: – At the end of 1 st year from the grant date - 20% of options granted. – At the end of 2 nd year from the grant date - 20% of options granted. – At the end of 3 rd year from the grant date - 20% of options granted. – At the end of 4 th year from the grant date - 40% of options granted.
6.	Time within which option may be exercised	All vested Options shall be exercisable within 5 years from the date of vesting of the respective Options or such other period as may be determined by the NRC from time to time.
7.	Options exercised	Not Applicable
8.	Money realized by exercise of Options	Not Applicable
9.	The total number of Shares arising as a result of exercise of Option	35000 Equity Shares of the face value Rs. 2/- each will arise deeming all granted options are vested and exercised.
10.	Options lapsed	Not Applicable
11.	Variation in terms of Options	Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

✉ info@rossari.com

🌐 www.rossari.com

Sr. No.	Particulars	Details
12.	Brief details of significant terms	The ESOP 2019 is administered by the NRC. The grant of Options by the NRC is based upon the eligibility criteria as per ESOP 2019. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes, in accordance with terms and conditions of the ESOP 2019. The Exercise Price of the Options granted to an Eligible Employee is determined by the NRC. Provided, however, the Exercise Price shall in no event be less than the face value of the Shares.
13.	Subsequent changes or cancellation or exercise of such Options	Not Applicable
14.	Diluted earnings per share pursuant to the issue of equity shares on exercise of Options	Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000
: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

 info@rossari.com

 www.rossari.com

Annexure-II
Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sr. No.	Particular	Disclosure – Rossari Employee Stock Option Plan – 2019
1.	Company name and address of Registered Office	Rossari Biotech Limited CIN: L24100MH2009PLC194818 Registered Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079.
2.	Name of the recognised Stock Exchanges on which the Company's shares are listed	1. BSE Limited (BSE) 2. National Stock Exchange of India Limited (NSE)
3.	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with recognised Stock Exchange	Filing date of statement is as follows: 1. BSE Limited: May 20, 2021 2. National Stock Exchange of India Limited: May 25, 2021
4.	Filing No., if any	BSE: 129899 NSE: 26888
5.	Title of the Scheme pursuant to which shares are issued, if any	Rossari Employee Stock Option Plan – 2019
6.	Kind of security to be listed	Equity Shares
7.	Par Value of the shares	Rs. 2/-
8.	Date of Issue of shares	October 15, 2025
9.	Number of shares issued	14,400 Shares
10.	Share Certificate No., if applicable	Not applicable
11.	Distinctive Number of the shares, if applicable	55366967 to 55381366 (both inclusive)
12.	ISIN of the shares if issued in Demat	INE02A801020
13.	Exercise price per share	Rs. 425/-
14.	Premium per share	Rs. 423/-
15.	Total Issued shares after this issue	55381366 Shares
16.	Total Issued share capital after this issue	Rs. 11,07,62,732
17.	Details of any lock-in on the shares	Not Applicable
18.	Date of expiry of lock-in	Not Applicable
19.	Whether shares identical in all respects to existing shares, if not, when will they become identical	All equity shares allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company
20.	Details of listing fees, if applicable	Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

info@rossari.com

www.rossari.com

Annexure-III

Details as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Rossari International Limited Company ("RILC"). RILC is a wholly owned subsidiary of the Company incorporated in Kingdom of Saudi Arabia. The financial details of RILC as on March 31, 2025 are as under: (i) Turnover: Nil and (ii) Net Worth: SAR 1.00 million.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	RILC is a wholly owned subsidiary and a related party of the Company. The proposed investment is a related party transaction and will be carried out on an arm's length basis. Save and except as mentioned above the Promoter/ Promoter Group/ Group Companies are not interested in the proposed transaction.
3.	Industry to which the entity being acquired belongs	Chemical Manufacturing and other Industry
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	RILC will be into manufacturing and trading activities including handling of distribution and sales of chemicals and consumer products. The aforesaid proposed investment is to support the business and other requirements of RILC.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6.	Indicative time period for completion of the acquisition	The capital infusion will be made in one or more tranches depending on the fund requirements upto March 31, 2027.

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

info@rossari.com

www.rossari.com



Sr. No.	Particulars	Details
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Subscription of shares in RILC will be by way of cash consideration.
8.	Cost of acquisition and/or the price at which the shares are acquired	The Company shall make additional capital investment of upto USD ~8 million in tranches.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	No change in ownership / percentage holding. The Company will continue to hold 100% of the total equity share capital.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	RILC is a wholly owned subsidiary of the Company incorporated on December 24, 2024 in Kingdom of Saudi Arabia. Last 3 years turnover: Not Applicable



ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000
: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

✉ info@rossari.com

🌐 www.rossari.com

Walker Chandlok & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **30 September 2025** and the consolidated year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. We did not review the interim financial results of four subsidiaries included in the Statement, whose financial results reflect total assets of ₹ 10,689.25 million as at 30 September 2025, and total revenues of ₹ 3,669.06 million and ₹ 7,298.16 million, total net profit after tax of ₹ 96.87 million and ₹ 212.71 million, total comprehensive income of ₹ 95.02 million and ₹ 209.24 million, for the quarter and six-months period ended on 30 September 2025, respectively, and cash flows (net) of ₹ (199.14) million for the six months period ended 30 September 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 4.48 million and ₹ 9.05 million and total comprehensive income of ₹ 4.50 million and ₹ 9.07 million, for the quarter and six-months period ended on 30 September 2025, respectively, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the interim financial information of four subsidiaries, which has not been reviewed by their auditors, whose interim financial information reflects total assets of ₹ 283.37 million as at 30 September 2025, and total revenues of ₹ 135.00 million and ₹ 137.98 million, total net profit/(loss) after tax of ₹ 2.57 million and ₹ (2.25) million, total comprehensive income of ₹ 2.48 million and ₹ (1.08) million, for the quarter and six-months period ended on 30 September 2025, respectively, and cash flows (net) of ₹ 19.39 million for the six months period ended 30 September 2025 as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.18 million and ₹ 0.82 million, and total comprehensive income of ₹ 0.18 million and ₹ 0.82 million for the quarter and six-months period ended on 30 September 2025 respectively, in respect of a joint venture, based on its interim financial information, which have not been reviewed by its auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the aforesaid subsidiaries and joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

For Walker Chandio & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Bharat Shetty

Partner

Membership No. 106815

UDIN: 25106815BMJIIM5311

Place: Mumbai


Date: 15 October 2025

Rossari Biotech Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and
Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Sr. No.	Particulars
	Subsidiaries
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited
6	Rossari Global DMCC
7	Rossari International Company Limited
	Step down subsidiaries
1	Rossari Biotech Trading FZE
2	Unistar Thai Co. Ltd
	Joint Venture
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
	Associate
1	Romakk Chemicals Private Limited



ROSSARI BIOTECH LIMITED
(AN ISO9001:2005 & 14001:2015 Certified Company)




Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Particulars	Quarter ended			Half Year Ended		Rs. in million
	30th September, 2025	30th June, 2025	30th September, 2024	30th September, 2025	30th September, 2024	Year Ended 31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	5,861.07	5,437.16	4,983.51	11,298.23	9,880.01	20,802.94
Other Income	16.04	12.00	7.19	28.04	16.67	40.09
Total Income	5,877.11	5,449.16	4,990.70	11,326.27	9,896.68	20,843.03
II EXPENSES						
Cost of materials consumed	4,072.12	3,343.99	3,243.63	7,416.11	6,083.97	12,996.44
Purchase of stock-in-trade	293.88	289.57	423.37	583.45	848.90	1,647.68
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(357.45)	79.92	(260.00)	(277.53)	(116.86)	(311.15)
Employee benefits expense	377.99	374.65	325.63	752.64	611.47	1,323.30
Finance costs	60.91	57.28	36.81	118.19	73.66	178.11
Depreciation and amortisation expenses	182.33	177.49	151.62	359.82	305.34	670.73
Other expenses	755.29	670.48	591.44	1,425.77	1,144.23	2,495.85
Total Expenses	5,385.07	4,993.38	4,512.50	10,378.45	8,950.71	19,000.96
III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]	492.04	455.78	478.20	947.82	945.97	1,842.07
IV Share of profit of joint venture and associate	4.68	5.21	2.90	9.89	5.00	9.78
V Profit before exceptional items and tax [III+IV]	496.72	460.99	481.10	957.71	950.97	1,851.85
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax [V-VI]	496.72	460.99	481.10	957.71	950.97	1,851.85
VIII Tax Expense						
Current tax charge	160.51	161.05	149.70	321.56	302.27	590.71
Deferred tax (credit)	(32.55)	(36.02)	(21.93)	(68.57)	(53.62)	(102.64)
Total Tax Expense	127.96	125.03	127.77	252.99	248.65	488.07
IX Profit after tax [VII-VIII]	368.76	335.96	353.33	704.72	702.32	1,363.78
X Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	(3.41)	(3.10)	0.04	(6.51)	0.07	(12.67)
ii Income tax relating to items that will not be reclassified to profit or loss	0.86	0.78	(0.01)	1.64	(0.02)	3.18
B Items that will be reclassified subsequently to profit or loss						
i Exchange difference on translation of foreign operations	(0.09)	1.26	-	1.17	-	(0.76)
Total other comprehensive income/(loss)	(2.64)	(1.06)	0.03	(3.70)	0.05	(10.25)
XI Total comprehensive income [IX + X]	366.12	334.90	353.36	701.02	702.37	1,353.53
Profit for the period/year attributable to						
Owners of the Company	368.76	335.96	353.33	704.72	702.32	1,363.78
Non Controlling Interest	-	-	-	-	-	-
	368.76	335.96	353.33	704.72	702.32	1,363.78
Other Comprehensive Income/(Loss) attributable to						
Owners of the Company	(2.64)	(1.06)	0.03	(3.70)	0.05	(10.25)
Non Controlling Interest	-	-	-	-	-	-
	(2.64)	(1.06)	0.03	(3.70)	0.05	(10.25)
Total Comprehensive Income attributable to						
Owners of the Company	366.12	334.90	353.36	701.02	702.37	1,353.53
Non Controlling Interest	-	-	-	-	-	-
	366.12	334.90	353.36	701.02	702.37	1,353.53
Paid up equity share capital (Face value of Rs 2.00 per share)	110.73	110.73	110.58	110.73	110.58	110.73
Other equity	-	-	-	-	-	11,743.76
Earnings per equity share (in Rs.)						
Basic	5.66*	6.07*	6.39*	12.76*	12.71*	24.66
Diluted	6.65*	6.06*	6.38*	12.74*	12.69*	24.63

*Not annualized



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 15th October, 2025.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The consolidated financial results include the financial results of three foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited, two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd., (100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).
4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.
5. During the half year ended 30th September, 2025, the Parent Company has allotted 375 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

For ROSSARI BIOTECH LIMITED

Place : Mumbai
Date : 15th October, 2025




EDWARD MENEZES
Executive Chairman
DIN:00149205

ROSSARI BIOTECH LIMITED

Consolidated Statement of Assets and Liabilities as at 30th September, 2025

Particulars	Rs. In million	
	As at 30th September, 2025	As at 31st March, 2025
ASSETS		
NON-CURRENT ASSETS		
(a) Property, Plant and Equipment	2,862.58	2,851.61
(b) Right of Use Assets	826.73	683.73
(c) Capital Work-in-Progress	2,474.88	1,401.87
(d) Goodwill	1,187.11	1,187.11
(e) Other Intangible Assets	1,156.25	1,261.00
(f) Investments accounted for using the equity method	271.29	262.76
(g) Financial Assets		
(i) Investments	2.12	2.11
(ii) Other Financial Assets	73.62	74.35
(h) Income Tax Assets (Net)	75.38	77.47
(i) Deferred Tax Assets (Net)	158.80	105.13
(j) Other Non-current Assets	650.30	623.33
TOTAL NON- CURRENT ASSETS	9,739.06	8,530.47
CURRENT ASSETS		
(a) Inventories	3,812.04	3,550.80
(b) Financial Assets		
(i) Investments	200.04	573.13
(ii) Trade Receivables	5,404.81	4,745.04
(iii) Cash and Cash Equivalents	355.02	442.02
(iv) Bank Balances other than (iii) above	164.70	129.61
(v) Loans	14.97	12.43
(vi) Other Financial Assets	48.17	32.31
(c) Other Current Assets	1,141.00	933.93
TOTAL CURRENT ASSETS	11,140.75	10,419.27
Non-Current Assets classified as held for sale	-	12.10
TOTAL ASSETS	20,879.81	18,961.84
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	110.73	110.73
(b) Other Equity	12,404.26	11,743.76
Equity Attributable to Owners of the Company	12,514.99	11,854.49
TOTAL EQUITY	12,514.99	11,854.49
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	1,187.87	1,000.32
(ii) Lease Liabilities	208.01	223.07
(b) Provisions	73.95	52.57
(c) Deferred Tax Liabilities (Net)	449.13	465.67
TOTAL NON CURRENT LIABILITIES	1,918.96	1,741.63
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	2,050.51	879.41
(ii) Lease Liabilities	80.08	77.18
(iii) Trade Payables		
a) total outstanding dues of Micro Enterprises and Small Enterprises	336.49	235.24
b) total outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	2,589.71	2,628.11
(iv) Other Financial Liabilities	1,069.32	1,148.71
(b) Other Current Liabilities	113.39	201.43
(c) Provisions	76.09	73.17
(d) Current Tax Liabilities (Net)	130.27	122.47
TOTAL CURRENT LIABILITIES	6,445.86	5,365.72
TOTAL EQUITY AND LIABILITIES	20,879.81	18,961.84



ROSSARI BIOTECH LIMITED
Consolidated Statement of Cash Flow for the half year ended 30th September, 2025

Particulars	Rs. In million	
	For the half year ended	For The half year ended
	30th September, 2025	30th September 2024
	Unaudited	Unaudited
A Cash flows from operating activities		
Profit before tax	957.71	950.97
Adjustments for:		
Depreciation and amortization expenses	359.82	305.34
Gain on disposal of property, plant and equipment (net)	(1.82)	(0.33)
Provision for expected credit loss (net)	2.50	21.70
Share-based payments expenses	15.99	3.90
Liabilities no longer required written back	-	(0.26)
Finance Costs	111.48	73.66
Interest Income	(6.56)	(3.85)
Share of profit in Joint Venture/Associate	(9.89)	(5.00)
Net gain on sale/fair value of investments	(7.13)	(11.92)
Fair value loss on financial instruments classified as fair value through profit or loss	-	0.53
Net Unrealised foreign exchange gain	(39.47)	(4.94)
Operating profit before working capital changes	1,382.63	1,329.80
Working Capital changes:		
(Increase) in Trade Receivables and other assets	(976.08)	(393.55)
(Increase) in Inventories	(261.24)	(452.12)
(Decrease) / Increase in Trade Payables and other liabilities	(83.97)	195.12
Cash generated from Operations	61.34	679.25
Income taxes paid (net of refunds)	(311.66)	(285.92)
Net cash (used in) / generated from operating activities	(250.32)	393.33
B Cash flows from investing activities		
Net redemption from / (investment in) Mutual Funds	380.21	(138.54)
Dividend Received from an associate#	-	0.00
Interest Received	7.65	2.58
Purchase of property, plant and equipment and other intangible assets	(1,417.87)	(582.51)
Proceeds from sale of property, plant and equipment	2.41	0.35
Increase in bank balances not considered as cash and cash equivalents (net)	(35.61)	(28.72)
Net cash used in investing activities	(1,063.21)	(746.84)
C Cash flows from financing activities		
Repayment of long term borrowings	-	-
Proceeds from long term borrowings (net of expenses)	187.55	407.91
Proceeds from / (Repayment) of short term borrowings (net)	1,171.11	(39.21)
Interest paid	(88.62)	(64.58)
Principal Payment of lease liabilities	(14.39)	(3.40)
Payment of interest on lease liabilities	(12.81)	-
Proceeds from Issue of equity shares	1.36	18.40
Dividend paid on equity shares	(27.68)	(27.65)
Net cash generated from financing activities	1,216.52	291.47
Net (decrease) in cash and cash equivalents (A+B+C)	(97.01)	(62.04)
Opening Cash and cash equivalents	442.02	251.70
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	10.01	4.92
Closing Cash and cash equivalents	355.02	194.58

below rounding off norms



Walker Chandio & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **30 September 2025** and year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandio & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Bharat Shetty

Partner

Membership No. 106815

UDIN: **25106815BMJIL4078**

Place: Mumbai

Date: 15 October 2025

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818



STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Particulars	Quarter ended			Half Year Ended		Rs. In million
	30th September, 2025	30th June, 2025	30th September, 2024	30th September, 2025	30th September, 2024	Year Ended 31st March, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I INCOME						
Revenue from operations	4,195.12	3,657.58	3,359.89	7,852.70	6,366.97	14,316.28
Other Income	13.97	17.42	10.81	31.39	23.40	57.42
Total Income	4,209.09	3,675.00	3,370.70	7,884.09	6,390.37	14,373.70
II EXPENSES						
Cost of materials consumed	2,508.67	2,117.43	2,126.60	4,626.10	3,426.40	8,111.17
Purchase of stock-in-trade	717.91	500.84	494.04	1,218.75	1,334.40	2,530.00
Changes in inventory of finished goods, work-in-progress and stock-in-trade	(142.09)	93.40	(155.11)	(48.69)	(110.57)	(170.42)
Employee benefit expenses	173.13	156.66	135.65	329.79	278.86	600.11
Finance costs	24.93	30.93	19.03	55.86	42.31	95.84
Depreciation and amortisation expenses	73.43	71.50	65.38	144.93	126.01	276.90
Other expenses	433.39	349.80	316.00	783.19	597.13	1,383.07
Total Expenses	3,789.37	3,320.56	3,001.59	7,109.93	5,694.54	12,826.67
III Profit before exceptional items and tax (I-II)	419.72	354.44	369.11	774.16	695.83	1,547.03
IV Exceptional items	-	-	-	-	-	-
V Profit before tax (III-IV)	419.72	354.44	369.11	774.16	695.83	1,547.03
VI Tax Expense						
Current tax charge	112.35	96.42	98.36	208.77	183.61	421.86
Deferred tax charge/(credit)	(5.12)	(4.31)	(3.44)	(9.43)	(5.25)	(22.25)
Total Tax Expense	107.23	92.11	94.92	199.34	178.36	399.61
VII Profit after tax (V-VI)	312.49	262.33	274.19	574.82	517.47	1,147.42
VIII Other comprehensive income / (loss)						
A Items that will not be reclassified to profit or loss						
i Remeasurements of the defined benefit plans	(0.93)	(0.94)	(0.04)	(1.87)	(0.08)	(3.75)
ii Income tax relating to items that will not be reclassified to profit or loss	0.23	0.24	0.01	0.47	0.02	0.94
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income/(loss)	(0.70)	(0.70)	(0.03)	(1.40)	(0.06)	(2.81)
IX Total comprehensive income (VII + VIII)	311.79	261.63	274.16	573.42	517.41	1,144.61
Paid up equity share capital (Face value of Rs 2 per share)	110.73	110.73	110.58	110.73	110.58	110.73
Other equity						10,661.01
X Earnings per equity share (in Rs.)						
Basic	5.64*	4.74*	4.96*	10.40*	9.36*	20.75
Diluted	5.64*	4.73*	4.95*	10.40*	9.35*	20.72

*Not annualized

RS

RS



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 15th October, 2025.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. During the quarter ended 30th September, 2025, the Company has allotted 375 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
5. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.

Place : Mumbai
Date : 15 October, 2025



For ROSSARI BIOTECH LIMITED



EDWARD MENEZES
Executive Chairman
DIN:00149205

Particulars	Rs. In million	
	As at	As at
	30th September, 2025	31st March, 2025
	Unaudited	Audited
ASSETS		
NON-CURRENT ASSETS		
(a) Property, Plant and Equipment	1,414.43	1,467.29
(b) Right of Use - Assets	402.25	242.63
(c) Capital Work-in-Progress	727.94	340.87
(d) Goodwill	10.60	10.60
(e) Other Intangible Assets	62.51	71.52
(f) Financial Assets		
(i) Investments	4,931.06	4,931.06
(ii) Other Financial Assets	35.92	35.72
(g) Income Tax Assets (Net)	21.44	21.44
(h) Deferred Tax Assets (Net)	76.08	66.18
(i) Other Non-current Assets	388.21	340.27
TOTAL NON-CURRENT ASSETS	8,070.44	7,527.58
CURRENT ASSETS		
(a) Inventories	1,828.64	1,788.31
(b) Financial Assets		
(i) Investments	200.03	452.88
(ii) Trade Receivables	4,571.66	3,746.02
(iii) Cash and Cash Equivalents	232.29	129.06
(iv) Bank Balances other than (iii) above	31.76	31.12
(v) Loans	364.78	355.98
(vi) Other Financial Assets	236.62	75.43
(c) Other Current Assets	492.05	390.73
TOTAL CURRENT ASSETS	7,957.83	6,969.53
Assets classified as held for sale	-	12.10
TOTAL ASSETS	16,028.27	14,509.21
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	110.73	110.73
(b) Other Equity	11,194.51	10,661.01
TOTAL EQUITY	11,305.24	10,771.74
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Lease Liabilities	157.34	163.66
(b) Provisions	37.71	30.65
TOTAL NON-CURRENT LIABILITIES	195.05	194.31
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	669.41	301.44
(ii) Lease Liabilities	38.43	31.83
(iii) Trade Payables		
a) total outstanding dues of Micro Enterprises and Small Enterprises	216.83	190.74
b) total outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	3,321.60	2,668.52
(iv) Other Financial Liabilities	93.69	140.41
(b) Other Current Liabilities	44.99	78.02
(c) Provisions	35.43	33.49
(d) Current Tax Liabilities (Net)	107.60	98.71
TOTAL CURRENT LIABILITIES	4,527.98	3,543.16
TOTAL EQUITY AND LIABILITIES	16,028.27	14,509.21

KS

E



Particulars	Rs. In million	
	For the half year ended	For the half year ended
	30th September, 2025	30th September, 2024
	Unaudited	Unaudited
A Cash flows from operating activities		
Profit before tax	774.16	695.83
Adjustments for:		
Depreciation and amortisation expenses	144.93	126.01
Loss/(Gain) on disposal of property, plant and equipment and other intangible assets (net)	(1.82)	(0.20)
Net gain on sale/fair value of investments	(5.87)	(11.17)
Allowance for doubtful debts	-	18.00
Share-based payments expenses	4.57	2.81
Liabilities no longer required written back	-	(0.26)
Finance Costs	49.16	42.31
Dividend Income#	-	0.00
Interest Income	(16.75)	(11.64)
Fair value loss on financial instruments classified as fair value through profit or loss	-	0.53
Net Unrealised foreign exchange (gain)	(20.67)	(8.53)
Operating profit before working capital changes	927.71	853.69
Working Capital Changes :		
Increase in Trade Receivables and other assets	(1,119.28)	(325.60)
Increase in Inventories	(40.33)	(97.11)
Increase in Trade Payables and other liabilities	594.38	262.62
Cash generated from Operations	362.48	693.60
Income taxes paid (net of refunds)	(199.86)	(164.92)
Net cash generated from/(used in) operating activities	162.62	528.68
B Cash flows from investing activities		
Net Redemption from / (Investment) in of Mutual Funds	258.72	(139.28)
Investment in subsidiaries	-	(2.28)
Loans repaid by subsidiary company	-	0.30
Dividend Received#	-	0.00
Interest Received	12.26	10.57
Purchase of property, plant and equipment and other intangible assets	(617.59)	(213.07)
Proceeds from sale of property, plant and equipment and intangible assets	2.41	0.55
Investments in Fixed Deposits (Net)	(1.91)	-
Increase in bank balances not considered as cash and cash equivalents (net)	(0.63)	-
Net cash used in investing activities	(346.74)	(343.21)
C Cash flows from financing activities		
Repayment of long term borrowing	-	(50.04)
Proceeds from / (Repayment of) short term borrowing (net)	367.98	(201.30)
Interest paid	(39.13)	(36.92)
Principal Payment of lease liabilities	(14.86)	(3.40)
Payment of interest on lease liabilities	(9.82)	-
Proceeds from Issue of equity shares	1.35	18.40
Dividend paid on equity shares	(27.68)	(27.65)
Net cash generated from / (used in) financing activities	277.84	(300.91)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	93.72	(115.44)
Opening Cash and cash equivalents	129.06	225.48
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	9.51	4.74
Closing Cash and cash equivalents	232.29	114.78
# below rounding off norms		

